Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 9/20 | 0.63 |
| ▸ | CSF1R | P07333 | 7/20 | 0.63 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | KIF5B | P33176 | 1/20 | 0.63 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.63 |
| ▸ | BRAF | P15056 | 6/20 | 0.60 |
| ▸ | EGFR | P00533 | 4/20 | 0.60 |
| ▸ | ABL1 | P00519 | 4/20 | 0.58 |
| ▸ | BCR | P11274 | 2/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943719 | 0.93 | RET (0.57) | KITCSF1RRETKIF5BCCDC6 | |
| SCHEMBL21944015 | 0.93 | KIT (0.60) | KITCSF1RRETKIF5BCCDC6 | |
| SCHEMBL21943716 | 0.90 | RET (0.64) | KITCSF1RRETKIF5BCCDC6 | |
| SCHEMBL21943062 | 0.89 | KIT (0.52) | KITCSF1RRETKIF5BCCDC6 | |
| SCHEMBL21942962 | 0.89 | RET (0.78) | KITCSF1RRETKIF5BCCDC6 | |
| SCHEMBL21942967 | 0.89 | RET (0.76) | KITCSF1RRETKIF5BCCDC6 | |
| SCHEMBL21943061 | 0.89 | KIT (0.52) | KITCSF1RRETKIF5BCCDC6 | |
| SCHEMBL21942974 | 0.88 | RET (0.66) | KITCSF1RRETKIF5BCCDC6 | |
| SCHEMBL21943494 | 0.88 | RET (0.81) | KITCSF1RRETKIF5BCCDC6 | |
| SCHEMBL21942970 | 0.87 | RET (0.66) | KITCSF1RRETKIF5BCCDC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | XIAMEN UNIVERSITY (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP4A11, CYP2D6, CYP3A43 | KIT 603/4885CSF1R 3749/4885RET 309/4885 |
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | CYP4A11, CYP2D6, CYP3A43 | KIT 603/4885CSF1R 3749/4885RET 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.